Marker Therapeutics, Inc. – NASDAQ:MRKR

Marker Therapeutics stock price today

$1.13
-2.36
-67.62%
Financial Health
0
1
2
3
4
5
6
7
8
9

Marker Therapeutics stock price monthly change

-33.27%
month

Marker Therapeutics stock price quarterly change

-33.27%
quarter

Marker Therapeutics stock price yearly change

-17.69%
year

Marker Therapeutics key metrics

Market Cap
30.59M
Enterprise value
N/A
P/E
-0.25
EV/Sales
-0.07
EV/EBITDA
0.01
Price/Sales
1.33
Price/Book
0.20
PEG ratio
N/A
EPS
-1.63
Revenue
3.32M
EBITDA
-12.82M
Income
-5.59M
Revenue Q/Q
-64.45%
Revenue Y/Y
-75.02%
Profit margin
-648.35%
Oper. margin
-645.64%
Gross margin
0.3%
EBIT margin
-645.64%
EBITDA margin
-386.07%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Marker Therapeutics stock price history

Marker Therapeutics stock forecast

Marker Therapeutics financial statements

Marker Therapeutics, Inc. (NASDAQ:MRKR): Profit margin
Jun 2023 762.65K 2.51M 329.87%
Sep 2023 257.60K -2.98M -1157.57%
Dec 2023 1.05M -2.74M -259.35%
Mar 2024 1.24M -2.39M -192.34%
Marker Therapeutics, Inc. (NASDAQ:MRKR): Analyst Estimates
2027 37.97M -5.54M -14.62%
  • Analysts Price target

  • Financials & Ratios estimates

Marker Therapeutics, Inc. (NASDAQ:MRKR): Debt to assets
Jun 2023 21955648 2.92M 13.3%
Sep 2023 19486567 2.77M 14.26%
Dec 2023 17127391 3.07M 17.95%
Mar 2024 14091899 2.30M 16.35%
Marker Therapeutics, Inc. (NASDAQ:MRKR): Cash Flow
Jun 2023 -7.05M 18.77M 736
Sep 2023 -1.12M 18.66M 479.27K
Dec 2023 -2.36M -18.66M 5.13K
Mar 2024 -3.83M 0 49.09K

Marker Therapeutics alternative data

Marker Therapeutics, Inc. (NASDAQ:MRKR): Employee count
Aug 2023 67
Sep 2023 67
Oct 2023 67
Nov 2023 67
Dec 2023 67
Jan 2024 67
Feb 2024 67
Mar 2024 67
Apr 2024 67
May 2024 8
Jun 2024 8
Jul 2024 8

Marker Therapeutics other data

60.78% +37.39%
of MRKR is owned by hedge funds
507.57K -1.44M
shares is hold by hedge funds

Marker Therapeutics, Inc. (NASDAQ:MRKR): Insider trades (number of shares)
Period Buy Sel
Dec 2024 554250 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
NEW ENTERPRISE ASSOCIATES 16, L.P. 10 percent owner
Common Stock 554,250 $3.2 $1,773,600
Purchase
WASSERMAN FREDERICK GERALD director
Common Stock 10,000 $2.41 $24,100
Purchase
ELMS STEVE director
Common Stock 1,142,857 $1.75 $2,000,000
Purchase
HOANG PETER L. director, officer: President an..
Common Stock 142,857 N/A N/A
Purchase
VERA JUAN officer: Chief Development Offi..
Common Stock 571,428 N/A N/A
Purchase
WILSON JOHN ROBERT director
Common Stock 1,714,285 N/A N/A
Purchase
NEW ENTERPRISE ASSOCIATES 16, L.P.
Common Stock 5,714,285 $1.75 $9,999,999
Purchase
BASKETT FOREST
Common Stock 5,714,285 $1.75 $9,999,999
Purchase
BEHBAHANI ALI
Common Stock 5,714,285 $1.75 $9,999,999
Purchase
CHANG CARMEN
Common Stock 5,714,285 N/A N/A
Insider Compensation
Mr. Peter L. Hoang MBA (1972) Pres, Chief Executive Officer & Director
$625,880
Mr. Anthony H. Kim (1976) Chief Financial Officer $550,910
Dr. Mythili Koneru M.D., Ph.D. (1978) Chief Medical Officer $538,600
Thursday, 19 December 2024
globenewswire.com
globenewswire.com
Tuesday, 17 December 2024
globenewswire.com
Tuesday, 10 December 2024
globenewswire.com
Tuesday, 26 November 2024
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Wednesday, 14 August 2024
globenewswire.com
Monday, 12 August 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Monday, 8 April 2024
globenewswire.com
Monday, 25 March 2024
globenewswire.com
Friday, 22 March 2024
GlobeNewsWire
Wednesday, 30 August 2023
GlobeNewsWire
Thursday, 1 June 2023
PennyStocks
Wednesday, 31 May 2023
InvestorPlace
Monday, 1 May 2023
PennyStocks
Thursday, 10 November 2022
Zacks Investment Research
Friday, 14 October 2022
PennyStocks
Monday, 7 March 2022
GlobeNewsWire
Thursday, 17 February 2022
Benzinga
Thursday, 20 January 2022
PennyStocks
Benzinga
Friday, 20 August 2021
Benzinga
Pulse2
Thursday, 19 August 2021
PRNewsWire
  • What's the price of Marker Therapeutics stock today?

    One share of Marker Therapeutics stock can currently be purchased for approximately $1.13.

  • When is Marker Therapeutics's next earnings date?

    Unfortunately, Marker Therapeutics's (MRKR) next earnings date is currently unknown.

  • Does Marker Therapeutics pay dividends?

    No, Marker Therapeutics does not pay dividends.

  • How much money does Marker Therapeutics make?

    Marker Therapeutics has a market capitalization of 30.59M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 63.23% to 3.31M US dollars.

  • What is Marker Therapeutics's stock symbol?

    Marker Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "MRKR".

  • What is Marker Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Marker Therapeutics?

    Shares of Marker Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Marker Therapeutics's key executives?

    Marker Therapeutics's management team includes the following people:

    • Mr. Peter L. Hoang MBA Pres, Chief Executive Officer & Director(age: 53, pay: $625,880)
    • Mr. Anthony H. Kim Chief Financial Officer(age: 49, pay: $550,910)
    • Dr. Mythili Koneru M.D., Ph.D. Chief Medical Officer(age: 47, pay: $538,600)
  • How many employees does Marker Therapeutics have?

    As Jul 2024, Marker Therapeutics employs 8 workers, which is 88% less then previous quarter.

  • When Marker Therapeutics went public?

    Marker Therapeutics, Inc. is publicly traded company for more then 23 years since IPO on 16 Jul 2002.

  • What is Marker Therapeutics's official website?

    The official website for Marker Therapeutics is markertherapeutics.com.

  • Where are Marker Therapeutics's headquarters?

    Marker Therapeutics is headquartered at 3200 Southwest Freeway, Houston, TX.

  • How can i contact Marker Therapeutics?

    Marker Therapeutics's mailing address is 3200 Southwest Freeway, Houston, TX and company can be reached via phone at +7 134006400.

Marker Therapeutics company profile:

Marker Therapeutics, Inc.

markertherapeutics.com
Exchange:

NASDAQ

Full time employees:

8

Industry:

Biotechnology

Sector:

Healthcare

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

3200 Southwest Freeway
Houston, TX 77027

CIK: 0001094038
ISIN: US57055L2060
CUSIP: 57055L107